Latest Articlesddd

Merck’s product Keytruda and Exelixis’ product Cabometyx are both winners

February 21, 2019 0

Keytruda and Cabometyx Are Both Winners Keytruda failed to meet co-primary endpoints in Pivotal Phase 3 …

The Week in Review #37

February 19, 2019 0

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …

Nektar presentation today at the ASCO genitourinary cancers symposium

February 15, 2019 0

Today, at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU) held at …

RegenxBio: An analyst and investor event focused on the firm’s ophthalmology program.

February 15, 2019 0

RegenxBio (RGNX), a clinical-stage gene therapy firm with a proprietary NAV® Technology Platform, will host an analyst and investor …

Exelixis’ excellent scientific and financial accomplishments

February 13, 2019 0

Exelixis’ (EXEL) financial results for the fourth quarter and full year 2018 are as inspiring as they are …

Portola: On the right track

February 12, 2019 0

Portola Pharmaceuticals (PTLA) announced full results from ANNEXA-4, Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa®  in …

Successful results were announced by uniQure for its gene therapy, AMT-061, on hemophilia B patients

February 11, 2019 0

The United States FDA granted Breakthrough Therapy Designation to AMT-061. The European Medicines Agency gave it …

End of the Year Decisions ~ Part 3

February 10, 2019 0

Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this …

ImmunoGen’s Report and Standing. Why Biogen Is Experiencing a Selloff

February 8, 2019 0

ImmunoGen & Biogen News About ImmunoGen ImmunoGen (IMGN) is a creator and developer of antibody-drug conjugates (ADCs) …

Halozyme signs another license agreement this time with argenx

February 5, 2019 0

Halozyme Therapeutics (HALO) and argenx (ARGX) announced a global collaboration and license agreement offering argenx the right to use …

RegenxBio product RGX-181 has been granted FDA Rare Pediatric Disease Designation for Batten Disease Condition known as CLN2

February 1, 2019 0

FDA Granted Rare Pediatric Disease Designation for RegenxBio’s Product RGX-181 for CLN2 RegenxBio RegenxBio (RGNX), a …

Merck’s superior accomplishments

February 1, 2019 0

Merck (MRK) announced its Q4 2018 financial results. The firm outperformed itself and delighted us with regard …

Agenus fincances through Tokenization. Amgen’s critics hit hard. Why BioTime could thrive on OncoCyte news

January 30, 2019 0

AGENUS Agenus (AGEN) announced the upcoming launch of its Biotech Electronic Security Token (BEST); the first digital security …

OncoCyte liquid biopsy proves its accuracy and superiority in the differential diagnoses of Lung Cancer

January 29, 2019 0

Can a liquid biopsy test be accurate enough for physicians to rely on in differentiating between …

Now You See It, Now You Don’t

January 28, 2019 0

Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be …

End of the Year Decisions Part 2

January 24, 2019 0

Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected …

CompuGen demonstrates the importance of its product COM701 targeting PVRIG in immunotherapy

January 22, 2019 0

Data published in Cancer Immunology Research indicate monotherapy and combination opportunities for COM701, a first-in-class cancer …

Lipocine’s product, LPCN-1144, has promising results in decreasing the risk of NASH in non-alcoholic fatty liver disease

January 17, 2019 0

Lipocine (LPCN), a specialty pharmaceutical company, announced that an approximately eight-week top-line study using LPCN 1144 …

The FDA committee voted 19 to 1 in favor of approving Amgen’s & UCB’s new osteoporosis product Evenity

January 17, 2019 0

On January 8, 2019 the osteoporosis monoclonal antibody Evenity (romosozumab) developed by Amgen and UCB was …

Another drug approval for Exelixis. Why Alnylam’s stock is under pressure today

January 15, 2019 0

More good news came  from Exelixis (EXEL). It was expected by many but not by those who …